Ask how randomization works, whether placebo is used, when/if participants may cross over, what standard care continues, and which results families will receive. Consent should match what the protocol actually promises.
What this means in real life
In a placebo-controlled trial, participants are assigned to investigational treatment or a comparison group, often by chance. Blinding means participants, investigators or both may not know the assignment. This reduces bias but can be emotionally difficult. Standard DMD care usually continues unless the protocol says otherwise; families should identify exactly what remains allowed.
An open-label extension may offer all eligible participants the investigational product after the blinded period, but it is not automatic proof of benefit and may have new eligibility, timing or supply conditions. Read the consent language carefully: “may be offered” is different from a guaranteed crossover. Ask whether placebo participants wait longer, whether dose differs and whether the sponsor can end the extension.
Understand what results an individual family will receive. Group results, treatment assignment, genetic findings, biopsies and incidental results can follow different timelines.
A practical checklist
- ✓
Ask for the randomization ratio and expected placebo duration.
- ✓
List all standard treatments that must remain stable, stop or are prohibited.
- ✓
Read the extension language for guarantees, conditions and timing.
- ✓
Plan emotionally and practically for either assignment.
- ✓
Ask when assignment and individual/group results will be shared.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- What chance is there of receiving placebo?
- What care continues in both groups?
- Could emergency staff learn the assignment if medically necessary?
- Is open-label access guaranteed, conditional or optional?
- What happens if the study drug is ineffective, unsafe or unavailable?
Important context
Individual needs, eligibility and safety can differ. Confirm the plan with the relevant Duchenne-experienced clinician, therapist, school team or program before acting.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.